BioAesthetics Announces University Clinical Study for its Nipple Reconstruction Graft
ncarol.com/10088647

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioAesthetics Corporation today announced a clinical study of its nipple reconstruction graft will be performed at Stanford Medicine beginning in 2021. The BioAesthetics® NACgraft™ biologic matrix is a decellularized skin allograft of the human nipple-areolar complex (NAC) intended to replace the NAC when lost due to mastectomy or other procedure. BioAesthetics hopes the NACgraft will improve the quality-of-life — including improved body-image and other positive psychological impacts — of those choosing to undergo breast reconstruction, as current available nipple reconstruction options such as prostheses, tattoos, and skin flap reconstructions have often-unsatisfactory results.

The clinical study will follow, over a 12-month period, 15 patients who receive nipple reconstruction with the BioAesthetics NACgraft and previously underwent autologous breast reconstruction as part of treatment for breast cancer. The primary goal of the study is to evaluate healing time, with the secondary objectives of assessing patients' satisfaction, well-being, self-esteem, body image, psychological well-being, nipple dimensions, and sensitivity. The study is listed on clinicaltrials.gov under "Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts."

More on ncarol.com

• Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
• Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
• Angels Of Dirt Premieres on Youtube, Announces Paige Keck Helmet Sponsorship for 2026 Season
• "They Said It Was Impossible": This Bottle Turns Any Freshwater Source Into Ice-Cold, Purified Drinking Water in Seconds
• Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development

Geoffrey C. Gurtner, MD, Professor of Surgery and Inaugural Vice Chairman of Surgery for Innovation at Stanford Medicine, is the principal investigator for the study. Also participating in the clinical study are Arash Momeni, MD, Assistant Professor of Surgery in the Division of Plastic and Reconstructive Surgery at Stanford Health Care, and Dung Nguyen, MD, Director of Breast Reconstruction at the Stanford Women's Cancer Center and the Director of Adult Plastics Clinic at Stanford Health Care.

The NACgraft, like other decellularized human tissues, is regulated as a human cell, tissue and cellular and tissue-based product (HCT/P) under section 361 of the Public Health Service (PHS) Act and 21 CFR Part 1271. Establishments engaged in manufacture of HCT/Ps are required to register with FDA, which BioAesthetics has done. BioAesthetics expects to begin offering its NACgraft to all patients, not just those enrolled in the clinical study, in 2021.

"I have been following BioAesthetics from the early days when the NACgraft was just an idea," said Scott K. Sullivan, MD, Founding Partner of the Center for Restorative Breast Surgery and the St. Charles Surgical Hospital and a member of BioAesthetics' Scientific Advisory Board. "Nipple reconstruction has been the limiting factor for a complete breast reconstruction. I'm excited to see this product become available to patients and look forward to offering it to mine."

"We are excited to collaborate with Stanford for this clinical study and look forward to offering the BioAesthetics NACgraft to all patients in 2021," said Nicholas C. Pashos, Ph.D., Founder and CEO of BioAesthetics. "I can hardly believe that what was just a late-night idea in graduate school is now ready for patients and hopefully will make a positive impact on their quality-of-life. I am proud of all of the hard work the BioAesthetics team has done and grateful for the support of our investors without whom this could not happen."

More on ncarol.com

• Dave Aronberg Named 2026 John C. Randolph Award Recipient by Palm Beach Fellowship of Christians & Jews
• General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
• Unseasonable Warmth Triggers Early Pest Season Along I-5 Corridor
• Bug Busters Expands Service Footprint With New Carrollton, Georgia Branch
• Why KULR Could Be a Quiet Enabler of Space-Based Solar Power (SBSP) Over The Long Term: KULR Technology Group, Inc. (NY SE American: KULR)

BioAesthetics recently announced that it surpassed its Series A funding goal with participating investors and previous seed investors including its Director Sandra Coufal, MD of Sibling Capital Ventures, IndieBio/SOSV, The Launch Place, FemHealth Ventures, NO/LA Angel Network, The Pelican Fund, New Orleans BioFund, Arizona Technology Investors, New Orleans Startup Fund, Hemi VC, and numerous individual angel investors.

For more information on BioAesthetics, visit https://bio-aesthetics.com/.

About BioAesthetics:

BioAesthetics Corporation is a biotechnology company focused on transforming lives through advancements in biomaterials. Its inaugural product is a tissue-engineered nipple-areolar complex graft (NACgraft™ biologic matrix) for patients who are undergoing breast reconstruction generally following breast cancer and mastectomy; the company is currently validating its clinical manufacturing process in preparation for clinical launch of NACgraft. In addition, it has a product pipeline focused on acellular regenerative grafts for advanced wound and reconstructive care. BioAesthetics was founded as a spin-out of Tulane University in New Orleans, LA and is now located in Research Triangle Park, NC.

---

Show All News | Report Violation